IRCT20220423054621N1 IRCT 2024-06-24 Bagheiat-allah University of Medical Sciences Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy Evaluation of the effect of oral eplerenone in the management of Acute Central Serous Chorioretinopathy 2024-06-29 anticipated 20 Complete https://irct.ir/trial/68381 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random allocation will be done using the random blocking method (blocks of four). The possible blocks are as follows: 1- AABB, 2- ABAB, 3- BABA, 4- BBAA, 5- BAAB, 6- ABBA. In this step, numbers (1 to 6) will be randomly selected using the table of random numbers. and this work is repeated 10 times until the sample volume is reached, Blinding description: The drugs of the two groups will be similar in terms of shape, color and packaging (the pharmaceutical company has been asked to make a placebo in the same packaging as the drug under study) and the patients and also the person evaluating the consequences of the status of assignment to the treatment groups And they will not know the hypothesis of the study. 3 Acute Central Serous Chorioretinopathy. Intervention 1: Intervention group: Patients in the case group will be treated with eplerenone oral tablets, at the rate of 50 mg per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after the start of treatment will be done by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued. Intervention 2: Control group: The patients of the case group will be treated with eye vit plus oral tablets (OPD Pharma), one pill per day for 12 weeks. Follow-up of patients in 1, 2, 3 months after the start of treatment will be done by measuring BCVA and SD-OCT. Whenever the disease improves during the treatment period, the drug will be discontinued. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There is no further information